Bacteria cocktail aims to boost cancer immunotherapy

NCT ID NCT04208958

Completed Disease control Sponsor: Vedanta Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors better. Researchers measured safety and how many patients saw their tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VE800 (a mix of 11 live bacteria) plus nivolumab (Opdivo)
What this could lead to: If it works, this could point toward a new way to boost the immune system to fight advanced cancers.
What could go wrong: This is an early, small study (56 people) testing safety and response. The bacteria mix may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma melanoma metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MELANOMA METASTATIC CANCER

Contacts and locations

Locations

Baylor Scott and White Center for Advanced Heart and Lung Disese

Dallas, Texas, 75246, United States
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
HonorHealth Research Institute

Scottsdale, Arizona, 85258, United States
Huntsman Cancer Institute and Hospital

Salt Lake City, Utah, 84112, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
New York University Medical Oncology Associates

New York, New York, 10016, United States
Pacific Hematology Oncology Associates

San Francisco, California, 94115, United States
Swedish Medical Oncology - First Hill

Seattle, Washington, 98104, United States
The Angeles Clinic and Research Institute - West Los Angeles Office

Santa Monica, California, 90404, United States
The Miriam Hospital

Providence, Rhode Island, 02906, United States
The University of Chicago

Chicago, Illinois, 60637, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of California Los Angeles

Santa Monica, California, 90404, United States
Washington University School of Medicine Siteman Cancer Center

St Louis, Missouri, 63110, United States
Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.